Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Washington National Institute on Aging (NIA) |
---|---|
Information provided by: | University of Washington |
ClinicalTrials.gov Identifier: | NCT00161473 |
The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease and other types of dementia in late life.
Condition | Intervention |
---|---|
Alzheimer Disease Psychomotor Agitation |
Drug: prazosin Drug: placebo |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Alzheimer's in Long-Term Care--Treatment for Agitation |
Estimated Enrollment: | 120 |
Study Start Date: | January 2001 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: prazosin
1-6 mg capsules bid for 8 weeks
|
2: Placebo Comparator |
Drug: placebo
placebo capsules bid for 8 weeks
|
Although the occurrence of disruptive agitation behaviors likely are influenced by environmental/ interpersonal factors, it is also likely that behaviorally relevant neurobiologic abnormalities lower the threshold for the expression of such behavior in AD. Because of the success prazosin has had in the treatment of PTSD, it is thought that it could be used similarly with disruptive agitation. Originally designed to evaluate AD patients in nursing homes, the study now includes outpatients. It is a 9-week placebo-controlled trial.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Beth Hutchings, PA-C | 1-800-317-5382 | elizabeth.hutchings@va.gov |
United States, Washington | |
Veterans Affairs Puget Sound Health Care System | Recruiting |
Seattle, Washington, United States, 98108 | |
Principal Investigator: Elaine R Peskind, MD |
Principal Investigator: | Elaine R Peskind, MD | Veterans Affairs Puget Sound Health Care System |
Responsible Party: | University of Washington School of Medicine/VA Puget Sound Health Care System ( Elaine R. Peskind, MD, Professor, Director of Clinical Research, Mental Health Service ) |
Study ID Numbers: | 16508 |
Study First Received: | September 8, 2005 |
Last Updated: | September 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00161473 |
Health Authority: | United States: Institutional Review Board |
double-blind treatment prazosin |
Alzheimer Disease Central Nervous System Diseases Psychomotor Agitation Brain Diseases Neurodegenerative Diseases Dyskinesias Cognition Disorders Signs and Symptoms |
Delirium, Dementia, Amnestic, Cognitive Disorders Prazosin Mental Disorders Neurologic Manifestations Dementia Neurobehavioral Manifestations Delirium |
Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Adrenergic alpha-Antagonists Cardiovascular Agents |
Antihypertensive Agents Pharmacologic Actions Therapeutic Uses Psychomotor Disorders Adrenergic Antagonists Tauopathies |